1-2 of 2
Lu Xie
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Longer versus Shorter Schedules of Vincristine, Irinotecan, and Temozolomide (VIT) for Relapsed or Refractory Ewing Sarcoma: A Randomized Controlled Phase 2 Trial

Jie Xu, Lu Xie, Xin Sun, Kuisheng Liu, Xin Liang, Zhenyu Cai, Xiaodong Tang, Wei Guo
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (6): 1040–1046.
https://doi.org/10.1158/1078-0432.CCR-22-3546
Published: 14 March 2023
View article titled, Longer versus Shorter Schedules of Vincristine, Irinotecan, and Temozolomide (VIT) for Relapsed or Refractory Ewing Sarcoma: A Randomized Controlled Phase 2 Trial
Open the PDF for Longer versus Shorter Schedules of Vincristine, Irinotecan, and Temozolomide (VIT) for Relapsed or Refractory Ewing Sarcoma: A Randomized Controlled Phase 2 Trial in another window
Includes: Supplementary data
Journal Articles

Phase II Study of TQB2450, a Novel PD-L1 Antibody, in Combination with Anlotinib in Patients with Locally Advanced or Metastatic Soft Tissue Sarcoma

Jiayong Liu, Tian Gao, Zhichao Tan, Shu Li, Jie Xu, Chujie Bai, Ruifeng Xue, Lu Xie, Lu Zhang, Zhengfu Fan, Wei Guo
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (16): 3473–3479.
https://doi.org/10.1158/1078-0432.CCR-22-0871
Published: 15 August 2022
View article titled, Phase II Study of TQB2450, a Novel PD-L1 Antibody, in Combination with Anlotinib in Patients with Locally Advanced or Metastatic Soft Tissue Sarcoma
Open the PDF for Phase II Study of TQB2450, a Novel PD-L1 Antibody, in Combination with Anlotinib in Patients with Locally Advanced or Metastatic Soft Tissue Sarcoma in another window
Includes: Supplementary data